Medication access and continuity: The experiences of dual-eligible psychiatric patients during the first 4 months of the medicare prescription drug benefit

American Journal of Psychiatry

Volumn 164, Issue 5, 2007, Pages 789-796

  West, Joyce C ^a   Wilk, Joshua E ^a   Muszynski, Irvin L ^a   Rae, Donald S ^a   Rubio Stipec, Maritza ^a   Alter, Carol L ^a   Narrow, William E ^a   Regier, Darrel A ^a  

^a AMERICAN PSYCHIATRIC ASSOCIATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; MOOD STABILIZER; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DRUG UTILIZATION; EMERGENCY WARD; FEMALE; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICARE; MENTAL PATIENT; MOOD DISORDER; PATIENT SELECTION; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT PLANNING;

EID: 34249299424     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.2007.164.5.789     Document Type: Article

References (30)

1. Crowley J, Ashner D, Elam L: State Medicaid Outpatient Prescription Drug Policies: Findings From a National Survey. Kaiser Commission on Medicaid and the Uninsured, 2005 Update. http://www.kff.org/medicaid/7381.cfm
2. Koyanagi C, Forquer S, Alfano E: Medicaid policies to contain psychiatric drug costs. Health Aff (Millwood) 2005; 24:536-544
3. Drake RJ, Pickles A, Bentall RP, Kinderman P, Haddock G, Tarrier N, Lewis SW: The evolution of insight, paranoia, and depression during early schizophrenia. Psychol Med 2004; 34: 285-292
4. Opler LA, Caton CL, Shrout P, Dominguez B, Kass FI: Symptom profiles and homelessness in schizophrenia. J Nerv Ment Dis 1994; 182:174-178
5. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56:241-247
6. Svarstad BL, Shireman TI, Sweeney JK: Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001; 52:805-811
7. Swanson JW, Swartz MS, Borm R, Hiday VA, Wagner HR, Burns BJ: Involuntary out-patient commitment and reduction of violent behavior in persons with severe mental illness. Br J Psychiatry 2000; 176:324-331
8. Hoadley J, Hargrave E, Cubanski J, Neuman T: An In-Depth Examination of Formularies and Other Features of Medicare Drug Plans, The Henry J. Kaiser Family Foundation: The Medicare Drug Benefit, April 2006. http://kff.org/ medicare/upload/7489.pdf
9. Centers for Medicare and Medicaid Services: Why Is CMS Requiring "All or Substantially All" of the Drugs in the Antidepressant, Antipsychotic, Anticonvulsant, Anticancer, Immunosuppressant and HIV/AIDS categories? http://www.cms.hhs.gov/PrescriptionDrugCovContra/Downloads/ FormularyGuidance AllorSubAll.pdf
10. Smalley WE, Griffin MR, Fought RL, Sullivan L, Ray WA: Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients. N Engl J Med 1995; 332:1612-1617
11. Delate T, Mager DE, Sheth J, Motheral BR: Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. Am J Manag Care 2005; 11:29-36
12. Hansen LB, Fernald D, Araya-Guerra R, Westfall JM, West D, Pace W: Pharmacy clarification of prescriptions ordered in primary care: a report from the Applied Strategies for Improving Patient Safety (ASIPS) collaborative. J Am Board Fam Med 2006; 19:24-30
13. Lehman AF, Steinwachs DM, Survey Co-Investigators of the PORT Project: Patterns of usual care for schizophrenia: initials results from the schizophrenia patient outcomes research team (PORT) client survey. Schizophr Bull 1998; 24:11-20
14. Pingitore DP, Scheffler RM, Sentell T, West JC: Comparison of psychiatrists and psychologists in clinical practice. Psychiatr Serv 2002; 53:977-983
15. West JC, Wilk J, Olfson M, Rae DS, Marcus S, Narrow WE, Pincus HA, Regier DA: Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv 2005; 56:283-291
16. West JC, Duffy FF, Wilk J, Rae DS, Narrow WE, Pincus HA, Regier DA: Patterns and quality of treatment for patients with major depressive disorder in routine psychiatric practice. Focus 2005; 3:43-50
17. Frakt AB, Pizer SD: A first look at the new Medicare prescription drug plans. Health Aff (Millwood) 2006; 25:W252-W261
18. Cubanski J, Neuman P: Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage. Health Aff (Millwood) 2007; 26:W1-W12
19. Kaiser Family Foundation: National Survey of Pharmacists and National Survey of Physicians: Findings on Medicare Part D, Medicare Policy Project and the Public Opinion and Media Research Program, September 2006. http://www.kff.org/kaiser polls/upload/7556.pdf
20. Smith V, Gifford K, Kramer S, Elam L: Observations on the Initial Implementation of the Medicare Prescription Drug Program: Perspectives of State Medicaid Directors Through a Focus Group Discussion, Kaiser Commission on Medicaid and the Uninsured, May 2006. http://www.kff.org/medicaid/upload/7520. pdf
21. Smith V, Gifford K, Kramer S, Elam L: The Transition of Dual Eligibles to Medicare Part D Prescription Drug Coverage: State Actions During Implementation: Results From a 50-State Snapshot, Kaiser Commission on Medicaid and the Uninsured, February 2006. http://www.kff.org/medicaid/upload/7467.pdf
22. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Revision. Am J Psychiatry 2000; 157(suppl)
23. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Bipolar Disorder, Revision. Am J Psychiatry 2002; 159(suppl)
24. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Schizophrenia, 2nd ed. Am J Psychiatry 2004; 161(suppl)
25. Weiden PJ, Kozma C, Grogg A, Locklear J: Partial compliance and risk or rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55:886-891
26. Tse G, Thompson D, Procyshyn RM: Generic clozapine: a cost-saving alternative to brand name clozapine? Pharmacoeconomics 2003; 21:1-11
27. Kluznik JC, Walbek NH, Farnsworth MG, Melstrom K: Clinical effects of a randomized switch of patients from Clozaril to generic clozapine. J Clin Psychiatry 2001; 62(suppl 5):14-17
28. Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA: Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006; 163:2090-2095
29. Donohue J: Mental health in the Medicare Part D drug benefit: a new regulatory model? Health Aff (Millwood) 2006; 25:707-719
30. Polsky D, Doshi JA, Bauer MS, Glick HA: Clinical trial-based cost-effectiveness analyses of antipsychotic use. Am J Psychiatry 2006; 163:2047-2056